MEGAPRO BIOMEDICAL CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.5 TWD | -0.61% |
|
+2.73% | +0.62% |
More news
| 1 day | -0.61% | ||
| 1 week | +2.73% | ||
| Current month | -10.91% | ||
| 1 month | -7.55% | ||
| 3 months | +11.36% | ||
| 6 months | -5.22% | ||
| Current year | +0.62% |
1 week
24.05
25.10
1 month
23.8528.65
Current year
20.4029.60
1 year
20.4035.10
3 years
15.9051.80
5 years
15.9051.80
10 years
15.9051.80
| Managers | Title | Age | Since |
|---|---|---|---|
Hsien Chih Wang
CEO | Chief Executive Officer | - | 01/14/01 |
Yi Hsiang Chiu
DFI | Director of Finance/CFO | - | 01/21/01 |
Yuan Hung Hsu
BRD | Director/Board Member | - | 01/14/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Wei Feng Chiang
CHM | Chairman | - | 18/15/18 |
Po Sung Huang
BRD | Director/Board Member | - | 08/21/08 |
Hsien Chih Wang
CEO | Chief Executive Officer | - | 01/14/01 |
MegaPro Biomedical Co Ltd is a Taiwan-based company mainly engaged in the development of new drugs with nanomedicine as the core. The Company mainly has two nanotechnology platforms including nanoparticle and nanocell. The Company's products include MPB-1514, MPB-1523, MPB-1734 and MPB-2043. MPB-1514 is mainly used to treat patients with anemia due to chronic kidney disease by intravenous injection. MPB-1523 is mainly used intravenously to diagnose patients with hepatocellular carcinoma. MPB-1734 is mainly used to treat patients with solid tumors by intravenous injection. MPB-2043 is mainly used intravenously to diagnose patients with metastases in the peripheral lymph nodes of the cancerous site.
| 1st Jan change | Capi. | |
|---|---|---|
| +0.62% | 48.79M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- 6827 Stock
